Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

9.520 -0.160 (-1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
What's Next: Arvinas's Earnings Preview
 
Via Benzinga
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
From Arvinas Inc.
Via GlobeNewswire
Critical Insights From Arvinas Analyst Ratings: What You Need To Know
 
Via Benzinga
The Latest Analyst Ratings For Arvinas
 
Via Benzinga
Analyst Ratings For Arvinas
 
Via Benzinga
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
From Arvinas Inc.
Via GlobeNewswire
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist. 
Via Talk Markets
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024
ARVN stock results show that Arvinas beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
From Arvinas Inc.
Via GlobeNewswire
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - 
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.